(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number
WO 2005/023779 A1

(51) International Patent Classification[7]: C07D 239/42, A61K 31/505, A61P 3/06

(21) International Application Number:
PCT/GB2004/003829

(22) International Filing Date:
8 September 2004 (08.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0321127.3	10 September 2003 (10.09.2003)	GB
0404859.1	4 March 2004 (04.03.2004)	GB

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOOTH, Rebecca, Jane** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **CITTERN, Peter, Anthony** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB). **CRABB, Jeffrey, Norman** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB). **HORBURY, John** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB). **JONES, David, Wyn, Calvert** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Hallen, Bristol, Avon BS10 7ZE (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Sodertalje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/023779 A1

(54) Title: CRYSTALLINE FORM OF BIS [(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID] CALCIUM SALT

(57) Abstract: Two polymorphic forms of bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6 -enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.